USPTO serial 88255707
INAGENE DIAGNOSTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 13, 2024
- Examiner
- SABAGH, LAILA TAREK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INAGENE DIAGNOSTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Advertising the goods and services of others focused on the application of personal genetic information for pain management, mental health and other comorbid conditions; developing promotional campaigns focused on the application of personal genetic information for pain management, mental health and other comorbid conditions, and marketing services, namely, marketing consultancy for businesses in the field of personal genetic information for pain management, mental health and other comorbid conditions, all the foregoing not including veterinary or plant applications | ACTIVE | — |
| 041 | Providing online non-downloadable audio and video recordings containing information in the field of medical testing services, namely, genetic testing and genetic screening over a global computer network | ACTIVE | — |
| 042 | Genetic testing and genetic screening services for scientific research purposes; scientific research in the fields of genomics and genetics; scientific research in the application of personal genetic information with respect to medical or nutritional treatments, pharmaceuticals and clinical trials; providing genetic-based nutritional and pharmaceutical research information via the internet and via printed publications; providing clinical laboratory testing services, namely, pharmacogenetic tests, gene sequencing-based tests and genotyping based on the assessment, development and application of human genomic discoveries in the pharmaceutical, informatics and human clinical diagnostic industries, all the foregoing not including veterinary or plant applications; medical research in the fields of genomics and genetics; providing genetic-based medical research information via the internet and via printed publications; medical research in the fields of pharmacogenomics and pharmacogenetics; providing temporary use of on-line non-downloadable software applications related to medical conditions addressed by medical testing services, namely, platform as a service (PAAS) featuring computer software and mobile device applications for accessing information in the field of pain management, mental health and other comorbid conditions; providing genetic testing information for patients and healthcare professionals via an internet website portal; online services relating to medical testing services, namely, providing genetic testing and genetic screening information for patients and healthcare professionals via an internet website portal | ACTIVE | — |
| 044 | Medical diagnostic testing services and providing medical information in the form of personalized reports online in the field of genetic testing for medical purposes; providing clinical laboratory testing services, namely, personalized medical tests based on the assessment, development and application of human genomic discoveries in the medical industry; online medical testing services, namely, genetic testing and genetic screening; Medical information services, namely, providing personalized information online in the field of genetic testing for medical purposes; medical information services, namely, reporting and providing feedback to patients and healthcare professionals on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, personal genetic information for pain management, mental health and other comorbid conditions and for understanding individual responses to medication, all the foregoing not including veterinary or plant applications; medical information services, namely, analyzing pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applications; medical information services, namely, preparation of reports on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, analyzing individual pharmacogenetics and the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applications | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks owned by Inagene Diagnostics Inc.
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INAGENE DIAGNOSTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 13, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 13, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 28, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 8, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 24, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 10, 2024 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Apr 10, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 10, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 10, 2024 | PGRR | PETITION GRANTED - RESPONSE RECEIVED | — |
| Apr 8, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| Mar 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2024 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jan 22, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 19, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 19, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 6, 2023 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 6, 2023 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 6, 2023 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 16, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 16, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2023 | ALIE | ASSIGNED TO LIE | — |
| Feb 6, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 6, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Aug 6, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Aug 6, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 24, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 6, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 6, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 6, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 6, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 3, 2021 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 3, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 3, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 3, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 3, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 3, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 29, 2020 | ALIE | ASSIGNED TO LIE | — |
| Nov 2, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 1, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| May 1, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| May 1, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 1, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 1, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 17, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 24, 2019 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 24, 2019 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 24, 2019 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Sep 24, 2019 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Aug 14, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 14, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 3, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 2, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 2, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 25, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 30, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 12, 2019 | NWAP | NEW APPLICATION ENTERED | — |